secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-004446
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health reports preliminary 2023 revenue ~$562-563M (+25% YoY); clinical test volumes up 39%
--------------------------------------------------------------------------------

- Full year 2023 revenue $562-563M, up 25% YoY; clinical test volume 172,900 (+39%).
- Q4 2023 revenue $153-154M (+21%); clinical tests 46,400 (+29%).
- Full year free cash flow approx. -$347M; cash and equivalents $1.2B as of Dec 31, 2023.
- Co-CEOs cite Shield blood test progress; expect FDA approval and IVD launch in 2024.
- Results are preliminary and unaudited; final audited results expected in February 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/0001193125-24-004446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524004446/d710991d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-004446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer